Individual Investors Who Hold 38% of Antengene Corporation Limited (HKG:6996) Gained 77%, Insiders Profited as Well
Individual Investors Who Hold 38% of Antengene Corporation Limited (HKG:6996) Gained 77%, Insiders Profited as Well
Key Insights
關鍵見解
- Significant control over Antengene by individual investors implies that the general public has more power to influence management and governance-related decisions
- The top 5 shareholders own 52% of the company
- 26% of Antengene is held by insiders
- 個人投資者對德騰基因的嚴格控制意味着公衆擁有更大的影響管理和治理相關決策的權力
- 前五名股東擁有公司52%的股份
- 德騰基因 26% 的股份由內部人士持有
If you want to know who really controls Antengene Corporation Limited (HKG:6996), then you'll have to look at the makeup of its share registry. We can see that individual investors own the lion's share in the company with 38% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
如果你想知道誰真正控制着德琪醫藥有限公司(HKG: 6996),那麼你必須看看其股票登記處的構成。我們可以看到,個人投資者擁有公司的大部分股份,所有權爲38%。換句話說,該集團面臨最大的上行潛力(或下行風險)。
Individual investors gained the most after market cap touched HK$931m last week, while insiders who own 26% also benefitted.
上週市值觸及9.31億港元后,個人投資者漲幅最大,而持有26%的內部人士也從中受益。
In the chart below, we zoom in on the different ownership groups of Antengene.
在下圖中,我們放大了Antengene的不同所有權群體。
What Does The Institutional Ownership Tell Us About Antengene?
關於德琪醫學,機構所有權告訴我們什麼?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。
Institutions have a very small stake in Antengene. That indicates that the company is on the radar of some funds, but it isn't particularly popular with professional investors at the moment. If the business gets stronger from here, we could see a situation where more institutions are keen to buy. When multiple institutional investors want to buy shares, we often see a rising share price. The past revenue trajectory (shown below) can be an indication of future growth, but there are no guarantees.
各機構在德琪醫藥中所持的股份很小。這表明該公司受到一些基金的關注,但目前在專業投資者中並不特別受歡迎。如果業務從此變得更加強大,我們可能會看到更多機構熱衷於收購的情況。當多個機構投資者想要購買股票時,我們經常會看到股價上漲。過去的收入軌跡(如下所示)可以預示未來的增長,但無法保證。
Hedge funds don't have many shares in Antengene. With a 26% stake, CEO Jay Mei is the largest shareholder. In comparison, the second and third largest shareholders hold about 9.3% and 6.9% of the stock.
對沖基金在安騰基因的股份不多。首席執行官傑伊·梅持有26%的股份,是最大股東。相比之下,第二和第三大股東持有約9.3%和6.9%的股份。
Our research also brought to light the fact that roughly 52% of the company is controlled by the top 5 shareholders suggesting that these owners wield significant influence on the business.
我們的研究還揭示了這樣一個事實,即該公司約有52%的股份由前五名股東控制,這表明這些所有者對業務具有重大影響。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is some analyst coverage of the stock, but it could still become more well known, with time.
雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種好做法。有一些分析師對這隻股票的報道,但隨着時間的推移,它仍可能變得更加廣爲人知。
Insider Ownership Of Antengene
德琪醫藥的內部所有權
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
不同國家對內部人士的定義可能略有不同,但董事會成員始終算在內。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認爲內部所有權是一件好事。但是,在某些情況下,這使其他股東更難追究董事會對決策的責任。
Our information suggests that insiders maintain a significant holding in Antengene Corporation Limited. It has a market capitalization of just HK$931m, and insiders have HK$243m worth of shares in their own names. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.
我們的信息表明,內部人士持有德琪醫藥有限公司的大量股份。它的市值僅爲9.31億港元,內部人士以自己的名義持有價值2.43億港元的股票。很高興看到內部人士對這項業務進行如此投資。可能值得檢查一下這些內部人士最近是否在買入。
General Public Ownership
一般公有制
With a 38% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Antengene. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
憑藉38%的所有權,主要由個人投資者組成的公衆對德琪有一定程度的影響力。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。
Private Equity Ownership
私募股權所有權
With a stake of 22%, private equity firms could influence the Antengene board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
私募股權公司持有22%的股份,可能會影響德騰基因董事會。有些人可能會喜歡這樣,因爲私募股權有時是追究管理層責任的激進分子。但是其他時候,私募股權在公司上市後正在售罄。
Private Company Ownership
私人公司所有權
It seems that Private Companies own 6.5%, of the Antengene stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
看來私營公司擁有德琪醫藥6.5%的股份。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。
Next Steps:
後續步驟:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Antengene (of which 1 is concerning!) you should know about.
儘管值得考慮擁有公司的不同群體,但還有其他因素更爲重要。比如風險。每家公司都有它們,我們已經發現了Antengene的2個警告信號(其中1個令人擔憂!)你應該知道。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果你像我一樣,你可能需要考慮這家公司是會成長還是會萎縮。幸運的是,您可以查看這份免費報告,其中顯示了分析師對其未來的預測。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?擔心內容嗎?直接聯繫我們。或者,發送電子郵件給編輯組(網址爲)simplywallst.com。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。